New opportunities in pancreatic cancer: RAS inhibitors, highly complex surgery and integrated care
Clínic-IDIBAPS, within the framework of the Clínic Barcelona Comprehensive Cancer Centre (4CB), is taking part in the development of new RAS inhibi...
Clínic-IDIBAPS, within the framework of the Clínic Barcelona Comprehensive Cancer Centre (4CB), is taking part in the development of new RAS inhibi...
For the first time, the list includes a female researcher from the Campus, oncologist Ana Arance.
Clínic-IDIBAPS, within the framework of the Clínic Barcelona Comprehensive Cancer Centre, is joining the 12th Cities Race against Pancreatic Cancer...
Ten projects involving researchers from Campus Clínic, within the framework of the Clínic Barcelona Comprehensive Cancer Centre (4CB), have been se...
A new care model integrated into the Clínic Barcelona Comprehensive Cancer Centre (4CB) to identify genetic predisposition to cancer, strengthen pr...
Clínic-IDIBAPS, within the framework of the Clínic Barcelona Comprehensive Cancer Centre (4CB), has played a prominent role at the European Society...
The Clínic Barcelona Comprehensive Cancer Centre (4CB) has appointed Dr Susana Puig as Director of Research and Dr Teresa Macarulla as Director of...
The selected projects will address challenges related to liver diseases, haematopoietic transplantation, work-related cancers, healthy ageing, colo...
Hospital Clínic Barcelona and the Vila Casas Foundation have promoted two new artistic interventions at the Cancer and Blood Diseases Institute (IC...
RAS inhibitors have opened a new chapter in the treatment of pancreatic cancer, but some tumours develop resistance to these drugs. Here, we explor...